Pathogenesis and Reversal Strategies for Cancer Cachexia Using Multi-Omics
Official title: Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics
Run by China Medical University, China · NCT07519837 · Data updated 2026-11-12
This study uses multiple omics methods and nutritional interventions to try to find causes and reversal strategies for cachexia in adults with gastrointestinal cancers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | China Medical University, China Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | March 18, 2026 |
| Main results expected | March 20, 2028 |
| Study ends | March 20, 2028 |
| Registry record updated | April 9, 2026 |
| Trial ID | NCT07519837 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically or cytologically confirmed gastrointestinal cancers (for example esophageal, hepatocellular, gastric, or cholangiocarcinoma) who can give informed consent and are undergoing primary lesion biopsy or endoscopic biopsy are ideal candidates.
✕Probably not a fit
Patients who are pregnant or lactating, have two or more concurrent primary tumors, have contraindications to surgery, or cannot cooperate due to cognitive or psychiatric disorders are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will combine imaging omics, pathological omics, metabolomics, and metagenomics to build an integrated molecular and clinical model of cancer-related cachexia. Adult patients with gastrointestinal malignancies who undergo biopsy will provide tissue and biological samples for multi-omics analysis. The trial includes an enhanced intervention arm for nutritionally high-risk patients, a standard nutritional intervention positive control, and a placebo negative control to validate intervention effects. Data will be used to map metabolic pathways, identify early biomarkers, and nominate precise therapeutic targets that could reverse muscle and fat loss.
Why it matters
Potential benefit: If successful, this approach could identify targets and interventions that slow or reverse muscle and fat loss, improving survival, treatment tolerance, and quality of life for patients with cancer cachexia.
How similar studies have gone: Previous observational omics studies have linked certain pathways to cachexia but few interventional programs have demonstrated true reversal, so this combined multi-omics plus interventional approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Signed informed consent form and voluntary participation in this study * Histologically and/or cytologically confirmed diagnosis of cancer * Patients with gastrointestinal malignancies, including: * Esophageal cancer * Hepatocellular carcinoma * Gastric cancer * Cholangiocarcinoma * Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy Exclusion Criteria: * Pregnant or lactating women * Presence of contraindications to surgery * Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate * Presence of two or more concurrent primary tumors
Where it's running
-
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China Recruiting
Study contacts
- Study coordinator: Hanwen Liu
- Email: X18941960007@126.com
- Phone: +86 18941960007
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Spatial multi-omics and AI-based early warning for pancreatic cancer cachexia
This study tests whether spatial multi-omics data can reveal how the tumor and body metabolism interact in pancreatic cancer cachexia and whether a multimodal AI model can predict cachexia early in adults with pancreatic ductal adenocarcinoma.
-
Validating lab assays, IV catheter techniques, and devices for endocrine, cardiometabolic, and musculoskeletal conditions
This project will test whether laboratory assays, IV catheter methods, and equipment give consistent, reliable results in adults with or without obesity-related, metabolic, or musculoskeletal conditions.
-
High-protein, plant-dominant diet for people with liver cirrhosis
This 6-month test compares a high-protein, mostly plant-based diet to a usual low-fat animal-protein diet in adults with decompensated cirrhosis who are awaiting kidney transplant to see which better preserves nutrition and muscle.
-
Examining how muscle loss affects disease progression
This study is trying to see how muscle loss affects the health and recovery of patients with liver cirrhosis, cancer, and those on breathing machines.
-
Exploring exercise and molecular factors in cancer-related muscle loss
This study tests whether exercise can help people with non-small cell lung cancer who are losing muscle mass feel better and improve their quality of life.
-
Understanding muscle loss in heart failure patients
This study looks at how factors like lifestyle and nutrition affect muscle loss in people with heart failure compared to healthy individuals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.